Radioligand therapy development is progressing rapidly, but success depends on selecting the right preclinical models, optimal study designs and translational strategies. Many programs stall due to gaps in model relevance, study design or isotopic selection. Join this webinar to explore how early, informed decisions can de-risk development, validate therapeutic targets and support clinical translation, from discovery through IND.
This webinar is designed for researchers, drug developers and translational scientists focused on radioligand therapy and other targeted therapeutic approaches. It will highlight how the integration of radiochemistry, robust preclinical models and well-designed studies can generate reliable and reproducible data to guide smarter development decisions.
Join the featured speakers to explore:
- How to choose preclinical tumor models that reflect relevant biology and target expression
- Radiochemistry considerations, including isotope selection and labeling strategies
- Best practices for designing preclinical studies that address key translational questions
- How to generate decision-ready data that supports clinical translation
- A case study from glioblastoma research, showing how a combination of FACs analysis and advanced [¹⁷⁷Lu]FAP-2886 imaging can be used to determine FAP targeting and therapeutic potential in the U87MG model
Register for this webinar to see how imaging-based readouts can transform radiopharmaceutical therapy, reduce risk and bring promising therapies closer to patients.
Speakers
Mike Batey, Senior Director, SMS Discovery, Perceptive
Mike Batey is a Preclinical Pharmacologist with over 25 years of experience in oncology drug discovery and tumor model development, focusing on clinically representative models of human cancer. He has held senior leadership positions across a variety of roles in academia, industry and CROs, gaining a comprehensive understanding of all phases of the drug development process, from initial candidate selection to clinical approval. With over 30 peer-reviewed publications, Mike has been serving as Senior Director at Perceptive Discovery since January 2025.
Message Presenter
Julian Goggi, PhD, Director, Discovery Research, Perceptive
Julian Luke Goggi, PhD, is a Translational Scientist with over 20 years of experience in radiopharmaceutical research and development, specializing in the development of radioligand therapies and diagnostic radiopharmaceuticals across oncology, neurology and metabolic diseases. He has held senior roles in Europe and Asia, managing multidisciplinary teams and collaborations, and has authored over 60 peer-reviewed publications. He is currently serving as Director and Scientific Lead at Perceptive Inc, overseeing IND-enabling studies for radioligand therapy development.
Message PresenterWho Should Attend?
This session is designed for scientific, translational and strategic leaders in radiopharmaceutical drug development who want to apply imaging readouts to generate stronger data, validate targets and accelerate clinical progress. Ideal attendees include:
- Chief Scientific Officers (CSOs) and Heads of R&D seeking to de-risk radioligand therapy and targeted therapeutic programs
- Translational and Preclinical Leads evaluating tumor models, study design and imaging strategies for drug discovery
- Clinical Development and Regulatory Affairs leaders looking for quantitative biodistribution and dosimetry data to support IND submissions
- Radiochemists and Imaging Scientists working on isotope selection, labeling methods and modality-specific analysis
- Business Development or Strategy Directors assessing investment in radiopharmaceutical or targeted oncology pipelines
- Researchers and Program Managers advancing novel RLTs, ADCs or small-molecule programs into translational studies
What You Will Learn
Attendees will gain insights into:
- How to select and validate preclinical tumor models to capture relevant target biology and translational endpoints
- Key radiochemistry considerations for isotope labeling and chelator strategies that ensure reliable data generation
- Best practices for designing biodistribution, dosimetry and efficacy studies that inform smarter clinical decisions
- How a glioblastoma case study ([¹⁷⁷Lu]FAP-2886 in the U87MG model) demonstrates target validation, efficacy readouts and multi-target expression profiling
Xtalks Partner
Perceptive
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account